Saxenda should not be used during pregnancy. The drug hasn’t been studied in human pregnancy. When Saxenda was given to pregnant females in animal studies, it caused congenital anomalies ...

More than half of people prescribed weight-loss drugs Saxenda and Wegovy over the past decade ended their treatment too early to realize meaningful health benefits, according to a study by a major ...

Saxenda continues to develop a dominant position in obesity pharmacotherapy however, and Novo Nordisk said the drug currently has a market share of 63% worldwide.

The study used the company's older GLP-1 agonist therapy Saxenda (liraglutide), which requires a daily injection, rather than its top-selling once-weekly obesity drug Wegovy (semaglutide), and ...

Apart from Victoza, which was approved for Type 2 diabetes in 2010, liraglutide also underpins Novo’s older weight loss drug Saxenda and its insulin-degludec-based diabetes combination therapy ...

Also Read: Novo Nordisk’s Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows Novo Nordisk asserts that compounded liraglutide products have a ...